Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?

Novo Nordisk (NVO) shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading above its 50-day moving average but below its 200-day moving average.NVO Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment ResearchSeveral factors in the past three months caused Novo Nordisk's stock to dip. In December ...